Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.
AuthorsRoberts, Darren L
Williams, Kaye J
Cowen, Rachel L
Eustace, A J
Tilby, Michael J
Pearson, D Graham
Ottley, Christopher J
Stratford, Ian J
AffiliationPaterson Institute for Cancer Research, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractBACKGROUND: Hypoxia is as an indicator of poor treatment outcome. Consistently, hypoxic HCT116 colorectal cancer cells are resistant to oxaliplatin, although the mechanistic basis is unclear. This study sought to investigate the relative contribution of HIF-1 (hypoxia-inducible factor-1)-mediated gene expression and drug penetrance to oxaliplatin resistance using three-dimensional spheroids. METHODS: Hypoxia-inducible factor-1alpha function was suppressed by the stable expression of a dominant-negative form in HCT116 cells (DN). Cells were drug exposed as monolayer or multicellular spheroid cultures. Cells residing at differing oxygenation status were isolated from Hoechst 33342-treated spheroids using flow cytometry. Sub-populations were subjected to clonogenic survival assays and to Inductively-Coupled Plasma Mass Spectroscopy to determine oxaliplatin uptake. RESULTS: In spheroids, a sensitivity gradient (hypoxic
CitationContribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. 2009, 101 (8):1290-7 Br. J. Cancer
JournalBritish Journal of Cancer
- SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
- Authors: Murono K, Tsuno NH, Kawai K, Sasaki K, Hongo K, Kaneko M, Hiyoshi M, Tada N, Nirei T, Sunami E, Takahashi K, Kitayama J
- Issue date: 2012 Mar
- Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116.
- Authors: Jin F, Ji H, Jia C, Brockmeier U, Hermann DM, Metzen E, Zhu Y, Chi B
- Issue date: 2012
- The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
- Authors: Pedraz-Cuesta E, Christensen S, Jensen AA, Jensen NF, Bunch L, Romer MU, Brünner N, Stenvang J, Pedersen SF
- Issue date: 2015 May 16
- In vitro studies on the mechanisms of oxaliplatin resistance.
- Authors: Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L
- Issue date: 2001 Nov
- Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
- Authors: Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, Xu RH
- Issue date: 2014 Feb 15